The goal of this clinical trial is to learn about oral immunotherapy in food allergic children \< 30 months of age. The main question it aims to answer is: What is the clinical- and cost-effectiveness of early low-dose oral immunotherapy aimed at long-term tolerance induction. Participants will receive oral immunotherapy for 1 year with a maintenance dose of 300 mg allergenic protein and are compared with food allergic infants not receiving oral immunotherapy to compare with natural tolerance development.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of patients with sustained unresponsiveness to consumption of a specific allergenic food 4 weeks after stopping the 1-year oral immunotherapy (OIT)
Timeframe: Timing of the OFC: week 57 (52 weeks of OIT, followed by a 4-week allergenic food-free interval)
Percentage of tolerant participants at week 78
Timeframe: week 78 = 6 months after stop of the 1-year oral immunotherapy
Cost-effectiveness ratio at 18 months (week 78).
Timeframe: 18 months (week 78).
Cost-utility ratio at 18 months (week 78).
Timeframe: 18 months (week 78): at the end of the study period.